English

Madrigal Pharmaceuticals, Inc.

EDGAR

MDGL Quarterly report (10-Q) · filed 2026-07-30

Annual consolidated revenue for 2025: about USD 958.4M, using the latest reported figures. The previous period, 2024, was about USD 180.1M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

364 million USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 364252000 USD Source

Operating margin

-15.46%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -56308000 USD Source
Revenue: 364252000 USD Source

Operating cash flow

23.3 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -144106000 USD Source
Operating Cash Flow: -167435000 USD Source

Free cash flow

19.1 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -144106000 USD Source
Operating Cash Flow: -167435000 USD Source
Capital Expenditure: 8102000 USD Source
Capital Expenditure: 3849000 USD Source

Cash and cash equivalents: 293 million USD 2026-06-30 Source
Exact value

292726000 USD
Long-term debt including current maturities: 341 million USD 2026-06-30 Source
Exact value

340794000 USD
Shares outstanding: 23.1 million shares 2026-06-30 Source
Exact value

23093974 shares

Reported share-count change

3.93% · 873 thousand shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

22221116 shares · 2025-06-30· Source
23093974 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

1.28 billion USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 287268000 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 958403000 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 637320000 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 311337000 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 364252000 USD · 2026-04-01 – 2026-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-07-30.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 7 of 11 periods available· newest 2025-12-31
Operating income: 9 of 11 periods available· newest 2025-12-31
Net income: 9 of 11 periods available· newest 2025-12-31
Operating cash flow: 9 of 11 periods available· newest 2025-12-31
Capital expenditure: 9 of 11 periods available· newest 2025-12-31
Total assets: 7 of 11 periods available· newest 2025-12-31
Total liabilities: 7 of 11 periods available· newest 2025-12-31
Current assets: 7 of 11 periods available· newest 2025-12-31
Current liabilities: 7 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 7 of 11 periods available· newest 2025-12-31
Long-term debt including current maturities: 4 of 11 periods available· newest 2025-12-31
Shares outstanding: 7 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+432.1%

Prior period

USD 180.13 million

2024-01-01 – 2024-12-31
Current period

USD 958.4 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

958403000 − 180133000 = 778270000 USD

180133000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
958403000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Madrigal Pharmaceuticals, Inc. · 2025-12-31 Madrigal Pharmaceuticals, Inc. (edgar:1157601) Year-over-year change in Revenue: 778270000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1157601?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 958403000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000162828026009514/mdgl-20251231.htm#1268077 Filing: 000162828026009514 Input fundies:Revenue: 180133000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000162828026009514/mdgl-20251231.htm#1268884 Filing: 000162828026009514
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 177.59 million

Prior period

−USD 465.89 million

2024-01-01 – 2024-12-31
Current period

−USD 288.3 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-288300000 − -465892000 = 177592000 USD

-465892000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-288300000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Madrigal Pharmaceuticals, Inc. · 2025-12-31 Madrigal Pharmaceuticals, Inc. (edgar:1157601) Year-over-year change in Net income: 177592000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1157601?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -288300000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000162828026009514/mdgl-20251231.htm#1534796 Filing: 000162828026009514 Input fundies:NetIncome: -465892000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000162828026009514/mdgl-20251231.htm#1374983 Filing: 000162828026009514
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 266.02 million

Prior period

−USD 455.57 million

2024-01-01 – 2024-12-31
Current period

−USD 189.55 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-189553000 − -455572000 = 266019000 USD

-455572000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-189553000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Madrigal Pharmaceuticals, Inc. · 2025-12-31 Madrigal Pharmaceuticals, Inc. (edgar:1157601) Year-over-year change in Operating cash flow: 266019000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1157601?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -189553000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000162828026009514/mdgl-20251231.htm#1432706 Filing: 000162828026009514 Input fundies:OperatingCashFlow: -455572000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000162828026009514/mdgl-20251231.htm#1433360 Filing: 000162828026009514
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-68.1%

Prior period

USD 1.46 million

2024-01-01 – 2024-12-31
Current period

USD 467,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

467000 − 1462000 = -995000 USD

1462000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
467000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Madrigal Pharmaceuticals, Inc. · 2025-12-31 Madrigal Pharmaceuticals, Inc. (edgar:1157601) Year-over-year change in Capital expenditure: -995000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1157601?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 467000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000162828026009514/mdgl-20251231.htm#1441661 Filing: 000162828026009514 Input fundies:CapitalExpenditure: 1462000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000162828026009514/mdgl-20251231.htm#1442221 Filing: 000162828026009514
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 958.4 million 100% of revenue
Operating costs Derived USD 1.26 billion 131% of revenue
Operating income −USD 300.1 million −31% of revenue
Tax, interest and other Derived −USD 11.8 million −1.2% of revenue
Net income −USD 288.3 million −30% of revenue

Cash

Operating cash flow −USD 189.55 million −20% of revenue
Capital expenditure USD 467,000 0% of revenue
Free cash flow Derived −USD 190.02 million −20% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2019 Not shown: operating income or net income is not reported.
2020 Not shown: operating income or net income is not reported.
2021 Not shown: operating income or net income is not reported.
2022 Not shown: operating income or net income is not reported.
2023 Not shown: operating income or net income is not reported.
2024 Operating loss: operating costs were 376% of revenue.
2025 Operating loss: operating costs were 131% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2019 2019-01-01 – 2019-12-31	0	94972000 Derived	-94972000	-11024000 Derived	-83948000	-41796000 Derived	Source 2019-01-01 – 2019-12-31: 0 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -94972000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -83948000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -41624000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 172000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	0	206673000 Derived	-206673000	-4429000 Derived	-202244000	-157895000 Derived	Source 2020-01-01 – 2020-12-31: 0 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -206673000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -202244000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -157561000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 334000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	0	242482000 Derived	-242482000	-636000 Derived	-241846000	-184126000 Derived	Source 2021-01-01 – 2021-12-31: 0 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -242482000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -241846000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -183917000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 209000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	0	293571000 Derived	-293571000	1779000 Derived	-295350000	-225074000 Derived	Source 2022-01-01 – 2022-12-31: 0 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -293571000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -295350000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -224857000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 217000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	0	380496000 Derived	-380496000	-6866000 Derived	-373630000	-325709000 Derived	Source 2023-01-01 – 2023-12-31: 0 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -380496000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -373630000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -324230000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 1479000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	180133000	678008000 Derived	-497875000	-31983000 Derived	-465892000	-457034000 Derived	Source 2024-01-01 – 2024-12-31: 180133000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -497875000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -465892000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -455572000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 1462000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	958403000	1258500000 Derived	-300097000	-11797000 Derived	-288300000	-190020000 Derived	Source 2025-01-01 – 2025-12-31: 958403000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -300097000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -288300000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -189553000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 467000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 958.4M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Revenue	0	Revenue: 0 Open source
20202020-12-31	Revenue	0	Revenue: 0 Open source
20212021-12-31	Revenue	0	Revenue: 0 Open source
20222022-12-31	Revenue	0	Revenue: 0 Open source
20232023-12-31	Revenue	0	Revenue: 0 Open source
20242024-12-31	Revenue	180133000	Revenue: 180133000 Open source
20252025-12-31	Revenue	958403000	Revenue: 958403000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

432.1% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20202020-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20212021-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20222022-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20232023-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20242024-12-31	Year over year	No prior comparable period	Revenue: 180133000 Open source Revenue: 0 Open source
20252025-12-31	Year over year	432.1%	Revenue: 958403000 Open source Revenue: 180133000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -31.3% 2025

Net margin -30.1% 2025

Free cash flow margin -19.8% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Operating margin	Not reported	Operating Income: -94972000 Open source Revenue: 0 Open source
20202020-12-31	Operating margin	Not reported	Operating Income: -206673000 Open source Revenue: 0 Open source
20212021-12-31	Operating margin	Not reported	Operating Income: -242482000 Open source Revenue: 0 Open source
20222022-12-31	Operating margin	Not reported	Operating Income: -293571000 Open source Revenue: 0 Open source
20232023-12-31	Operating margin	Not reported	Operating Income: -380496000 Open source Revenue: 0 Open source
20242024-12-31	Operating margin	-276.4%	Operating Income: -497875000 Open source Revenue: 180133000 Open source
20252025-12-31	Operating margin	-31.3%	Operating Income: -300097000 Open source Revenue: 958403000 Open source
20192019-12-31	Net margin	Not reported	Net Income: -83948000 Open source Revenue: 0 Open source
20202020-12-31	Net margin	Not reported	Net Income: -202244000 Open source Revenue: 0 Open source
20212021-12-31	Net margin	Not reported	Net Income: -241846000 Open source Revenue: 0 Open source
20222022-12-31	Net margin	Not reported	Net Income: -295350000 Open source Revenue: 0 Open source
20232023-12-31	Net margin	Not reported	Net Income: -373630000 Open source Revenue: 0 Open source
20242024-12-31	Net margin	-258.6%	Net Income: -465892000 Open source Revenue: 180133000 Open source
20252025-12-31	Net margin	-30.1%	Net Income: -288300000 Open source Revenue: 958403000 Open source
20192019-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -41624000 Open source Capital Expenditure: 172000 Open source
20202020-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -157561000 Open source Capital Expenditure: 334000 Open source
20212021-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -183917000 Open source Capital Expenditure: 209000 Open source
20222022-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -224857000 Open source Capital Expenditure: 217000 Open source
20232023-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -324230000 Open source Capital Expenditure: 1479000 Open source
20242024-12-31	Free cash flow margin	-253.7%	Revenue: 180133000 Open source Operating Cash Flow: -455572000 Open source Capital Expenditure: 1462000 Open source
20252025-12-31	Free cash flow margin	-19.8%	Revenue: 958403000 Open source Operating Cash Flow: -189553000 Open source Capital Expenditure: 467000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -189.6M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Operating cash flow	-41624000	Operating Cash Flow: -41624000 Open source
20202020-12-31	Operating cash flow	-157561000	Operating Cash Flow: -157561000 Open source
20212021-12-31	Operating cash flow	-183917000	Operating Cash Flow: -183917000 Open source
20222022-12-31	Operating cash flow	-224857000	Operating Cash Flow: -224857000 Open source
20232023-12-31	Operating cash flow	-324230000	Operating Cash Flow: -324230000 Open source
20242024-12-31	Operating cash flow	-455572000	Operating Cash Flow: -455572000 Open source
20252025-12-31	Operating cash flow	-189553000	Operating Cash Flow: -189553000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -190M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Free cash flow	-41796000	Operating Cash Flow: -41624000 Open source Capital Expenditure: 172000 Open source
20202020-12-31	Free cash flow	-157895000	Operating Cash Flow: -157561000 Open source Capital Expenditure: 334000 Open source
20212021-12-31	Free cash flow	-184126000	Operating Cash Flow: -183917000 Open source Capital Expenditure: 209000 Open source
20222022-12-31	Free cash flow	-225074000	Operating Cash Flow: -224857000 Open source Capital Expenditure: 217000 Open source
20232023-12-31	Free cash flow	-325709000	Operating Cash Flow: -324230000 Open source Capital Expenditure: 1479000 Open source
20242024-12-31	Free cash flow	-457034000	Operating Cash Flow: -455572000 Open source Capital Expenditure: 1462000 Open source
20252025-12-31	Free cash flow	-190020000	Operating Cash Flow: -189553000 Open source Capital Expenditure: 467000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

52.2% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Liabilities / assets	5.8%	Total Liabilities: 25491000 Open source Total Assets: 442056000 Open source
20202020-12-31	Liabilities / assets	16.4%	Total Liabilities: 47025000 Open source Total Assets: 286995000 Open source
20212021-12-31	Liabilities / assets	28.3%	Total Liabilities: 77225000 Open source Total Assets: 273332000 Open source
20222022-12-31	Liabilities / assets	45.6%	Total Liabilities: 165183000 Open source Total Assets: 362572000 Open source
20232023-12-31	Liabilities / assets	36.7%	Total Liabilities: 235214000 Open source Total Assets: 640547000 Open source
20242024-12-31	Liabilities / assets	27.6%	Total Liabilities: 287864000 Open source Total Assets: 1042247000 Open source
20252025-12-31	Liabilities / assets	52.2%	Total Liabilities: 656900000 Open source Total Assets: 1259589000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

4.01× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Current assets / current liabilities	17.52×	Current Assets: 440197000 Open source Current Liabilities: 25130000 Open source
20202020-12-31	Current assets / current liabilities	6.13×	Current Assets: 285163000 Open source Current Liabilities: 46557000 Open source
20212021-12-31	Current assets / current liabilities	3.54×	Current Assets: 271684000 Open source Current Liabilities: 76838000 Open source
20222022-12-31	Current assets / current liabilities	3.12×	Current Assets: 361369000 Open source Current Liabilities: 115894000 Open source
20232023-12-31	Current assets / current liabilities	5.38×	Current Assets: 637281000 Open source Current Liabilities: 118548000 Open source
20242024-12-31	Current assets / current liabilities	6.1×	Current Assets: 1032927000 Open source Current Liabilities: 169277000 Open source
20252025-12-31	Current assets / current liabilities	4.01×	Current Assets: 1245770000 Open source Current Liabilities: 310288000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2017 2017-01-01 – 2017-12-31	−USD 31.15 million Exact value Exact value: -31154000 USD 2017-01-01 – 2017-12-31: -31154000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Madrigal Pharmaceuticals, Inc. · 2017-12-31 Madrigal Pharmaceuticals, Inc. (edgar:1157601) Net Income: -31154000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1157601/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -31154000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000119312520049021/d796399d10k.htm#1473738 Filing: 000119312520049021 The citation records this snapshot. The page link may show a newer release later.	−USD 22.32 million Exact value Exact value: -22317000 USD 2017-01-01 – 2017-12-31: -22317000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Madrigal Pharmaceuticals, Inc. · 2017-12-31 Madrigal Pharmaceuticals, Inc. (edgar:1157601) Operating Cash Flow: -22317000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1157601/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -22317000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000119312520049021/d796399d10k.htm#1663649 Filing: 000119312520049021 The citation records this snapshot. The page link may show a newer release later.	USD 125,000 Exact value Exact value: 125000 USD 2017-01-01 – 2017-12-31: 125000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Madrigal Pharmaceuticals, Inc. · 2017-12-31 Madrigal Pharmaceuticals, Inc. (edgar:1157601) Capital Expenditure: 125000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1157601/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 125000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000119312520049021/d796399d10k.htm#1677812 Filing: 000119312520049021 The citation records this snapshot. The page link may show a newer release later.	−USD 22.44 million Calculation and evidence -22317000 − 125000 USD Exact free cash flow: -22442000 USD 2017-01-01 – 2017-12-31: -22317000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 125000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Madrigal Pharmaceuticals, Inc. · 2017-12-31 Madrigal Pharmaceuticals, Inc. (edgar:1157601) Free cash flow: -22442000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1157601?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -22317000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000119312520049021/d796399d10k.htm#1663649 Filing: 000119312520049021 Input fundies:CapitalExpenditure: 125000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000119312520049021/d796399d10k.htm#1677812 Filing: 000119312520049021 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 32.81 million Exact value Exact value: -32811000 USD 2018-01-01 – 2018-12-31: -32811000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Madrigal Pharmaceuticals, Inc. · 2018-12-31 Madrigal Pharmaceuticals, Inc. (edgar:1157601) Net Income: -32811000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1157601/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -32811000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000119312521056164/d103755d10k.htm#1144553 Filing: 000119312521056164 The citation records this snapshot. The page link may show a newer release later.	−USD 25.51 million Exact value Exact value: -25507000 USD 2018-01-01 – 2018-12-31: -25507000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Madrigal Pharmaceuticals, Inc. · 2018-12-31 Madrigal Pharmaceuticals, Inc. (edgar:1157601) Operating Cash Flow: -25507000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1157601/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -25507000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000119312521056164/d103755d10k.htm#1228153 Filing: 000119312521056164 The citation records this snapshot. The page link may show a newer release later.	USD 22,000 Exact value Exact value: 22000 USD 2018-01-01 – 2018-12-31: 22000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Madrigal Pharmaceuticals, Inc. · 2018-12-31 Madrigal Pharmaceuticals, Inc. (edgar:1157601) Capital Expenditure: 22000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1157601/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 22000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000119312521056164/d103755d10k.htm#1236727 Filing: 000119312521056164 The citation records this snapshot. The page link may show a newer release later.	−USD 25.53 million Calculation and evidence -25507000 − 22000 USD Exact free cash flow: -25529000 USD 2018-01-01 – 2018-12-31: -25507000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 22000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Madrigal Pharmaceuticals, Inc. · 2018-12-31 Madrigal Pharmaceuticals, Inc. (edgar:1157601) Free cash flow: -25529000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1157601?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -25507000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000119312521056164/d103755d10k.htm#1228153 Filing: 000119312521056164 Input fundies:CapitalExpenditure: 22000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000119312521056164/d103755d10k.htm#1236727 Filing: 000119312521056164 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 83.95 million Exact value Exact value: -83948000 USD 2019-01-01 – 2019-12-31: -83948000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Madrigal Pharmaceuticals, Inc. · 2019-12-31 Madrigal Pharmaceuticals, Inc. (edgar:1157601) Net Income: -83948000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1157601/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -83948000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000119312522051569/d243442d10k.htm#1216619 Filing: 000119312522051569 The citation records this snapshot. The page link may show a newer release later.	−USD 41.62 million Exact value Exact value: -41624000 USD 2019-01-01 – 2019-12-31: -41624000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Madrigal Pharmaceuticals, Inc. · 2019-12-31 Madrigal Pharmaceuticals, Inc. (edgar:1157601) Operating Cash Flow: -41624000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1157601/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -41624000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000119312522051569/d243442d10k.htm#1307498 Filing: 000119312522051569 The citation records this snapshot. The page link may show a newer release later.	USD 172,000 Exact value Exact value: 172000 USD 2019-01-01 – 2019-12-31: 172000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Madrigal Pharmaceuticals, Inc. · 2019-12-31 Madrigal Pharmaceuticals, Inc. (edgar:1157601) Capital Expenditure: 172000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1157601/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 172000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000119312522051569/d243442d10k.htm#1316603 Filing: 000119312522051569 The citation records this snapshot. The page link may show a newer release later.	−USD 41.8 million Calculation and evidence -41624000 − 172000 USD Exact free cash flow: -41796000 USD 2019-01-01 – 2019-12-31: -41624000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 172000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Madrigal Pharmaceuticals, Inc. · 2019-12-31 Madrigal Pharmaceuticals, Inc. (edgar:1157601) Free cash flow: -41796000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1157601?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -41624000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000119312522051569/d243442d10k.htm#1307498 Filing: 000119312522051569 Input fundies:CapitalExpenditure: 172000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000119312522051569/d243442d10k.htm#1316603 Filing: 000119312522051569 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 202.24 million Exact value Exact value: -202244000 USD 2020-01-01 – 2020-12-31: -202244000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Madrigal Pharmaceuticals, Inc. · 2020-12-31 Madrigal Pharmaceuticals, Inc. (edgar:1157601) Net Income: -202244000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1157601/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -202244000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000119312523060052/d468763d10ka.htm#354495 Filing: 000119312523060052 The citation records this snapshot. The page link may show a newer release later.	−USD 157.56 million Exact value Exact value: -157561000 USD 2020-01-01 – 2020-12-31: -157561000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Madrigal Pharmaceuticals, Inc. · 2020-12-31 Madrigal Pharmaceuticals, Inc. (edgar:1157601) Operating Cash Flow: -157561000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1157601/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -157561000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000119312523060052/d468763d10ka.htm#438632 Filing: 000119312523060052 The citation records this snapshot. The page link may show a newer release later.	USD 334,000 Exact value Exact value: 334000 USD 2020-01-01 – 2020-12-31: 334000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Madrigal Pharmaceuticals, Inc. · 2020-12-31 Madrigal Pharmaceuticals, Inc. (edgar:1157601) Capital Expenditure: 334000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1157601/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 334000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000119312523060052/d468763d10ka.htm#446057 Filing: 000119312523060052 The citation records this snapshot. The page link may show a newer release later.	−USD 157.9 million Calculation and evidence -157561000 − 334000 USD Exact free cash flow: -157895000 USD 2020-01-01 – 2020-12-31: -157561000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 334000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Madrigal Pharmaceuticals, Inc. · 2020-12-31 Madrigal Pharmaceuticals, Inc. (edgar:1157601) Free cash flow: -157895000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1157601?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -157561000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000119312523060052/d468763d10ka.htm#438632 Filing: 000119312523060052 Input fundies:CapitalExpenditure: 334000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000119312523060052/d468763d10ka.htm#446057 Filing: 000119312523060052 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 241.85 million Exact value Exact value: -241846000 USD 2021-01-01 – 2021-12-31: -241846000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Madrigal Pharmaceuticals, Inc. · 2021-12-31 Madrigal Pharmaceuticals, Inc. (edgar:1157601) Net Income: -241846000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1157601/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -241846000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000162828024007376/mdgl-20231231.htm#1155401 Filing: 000162828024007376 The citation records this snapshot. The page link may show a newer release later.	−USD 183.92 million Exact value Exact value: -183917000 USD 2021-01-01 – 2021-12-31: -183917000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Madrigal Pharmaceuticals, Inc. · 2021-12-31 Madrigal Pharmaceuticals, Inc. (edgar:1157601) Operating Cash Flow: -183917000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1157601/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -183917000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000162828024007376/mdgl-20231231.htm#1240948 Filing: 000162828024007376 The citation records this snapshot. The page link may show a newer release later.	USD 209,000 Exact value Exact value: 209000 USD 2021-01-01 – 2021-12-31: 209000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Madrigal Pharmaceuticals, Inc. · 2021-12-31 Madrigal Pharmaceuticals, Inc. (edgar:1157601) Capital Expenditure: 209000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1157601/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 209000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000162828024007376/mdgl-20231231.htm#1247374 Filing: 000162828024007376 The citation records this snapshot. The page link may show a newer release later.	−USD 184.13 million Calculation and evidence -183917000 − 209000 USD Exact free cash flow: -184126000 USD 2021-01-01 – 2021-12-31: -183917000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 209000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Madrigal Pharmaceuticals, Inc. · 2021-12-31 Madrigal Pharmaceuticals, Inc. (edgar:1157601) Free cash flow: -184126000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1157601?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -183917000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000162828024007376/mdgl-20231231.htm#1240948 Filing: 000162828024007376 Input fundies:CapitalExpenditure: 209000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000162828024007376/mdgl-20231231.htm#1247374 Filing: 000162828024007376 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 295.35 million Exact value Exact value: -295350000 USD 2022-01-01 – 2022-12-31: -295350000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Madrigal Pharmaceuticals, Inc. · 2022-12-31 Madrigal Pharmaceuticals, Inc. (edgar:1157601) Net Income: -295350000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1157601/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -295350000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000162828025007980/mdgl-20241231.htm#1858691 Filing: 000162828025007980 The citation records this snapshot. The page link may show a newer release later.	−USD 224.86 million Exact value Exact value: -224857000 USD 2022-01-01 – 2022-12-31: -224857000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Madrigal Pharmaceuticals, Inc. · 2022-12-31 Madrigal Pharmaceuticals, Inc. (edgar:1157601) Operating Cash Flow: -224857000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1157601/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -224857000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000162828025007980/mdgl-20241231.htm#1402155 Filing: 000162828025007980 The citation records this snapshot. The page link may show a newer release later.	USD 217,000 Exact value Exact value: 217000 USD 2022-01-01 – 2022-12-31: 217000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Madrigal Pharmaceuticals, Inc. · 2022-12-31 Madrigal Pharmaceuticals, Inc. (edgar:1157601) Capital Expenditure: 217000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1157601/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 217000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000162828025007980/mdgl-20241231.htm#1411057 Filing: 000162828025007980 The citation records this snapshot. The page link may show a newer release later.	−USD 225.07 million Calculation and evidence -224857000 − 217000 USD Exact free cash flow: -225074000 USD 2022-01-01 – 2022-12-31: -224857000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 217000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Madrigal Pharmaceuticals, Inc. · 2022-12-31 Madrigal Pharmaceuticals, Inc. (edgar:1157601) Free cash flow: -225074000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1157601?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -224857000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000162828025007980/mdgl-20241231.htm#1402155 Filing: 000162828025007980 Input fundies:CapitalExpenditure: 217000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000162828025007980/mdgl-20241231.htm#1411057 Filing: 000162828025007980 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 373.63 million Exact value Exact value: -373630000 USD 2023-01-01 – 2023-12-31: -373630000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Madrigal Pharmaceuticals, Inc. · 2023-12-31 Madrigal Pharmaceuticals, Inc. (edgar:1157601) Net Income: -373630000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1157601/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -373630000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000162828026009514/mdgl-20251231.htm#1353472 Filing: 000162828026009514 The citation records this snapshot. The page link may show a newer release later.	−USD 324.23 million Exact value Exact value: -324230000 USD 2023-01-01 – 2023-12-31: -324230000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Madrigal Pharmaceuticals, Inc. · 2023-12-31 Madrigal Pharmaceuticals, Inc. (edgar:1157601) Operating Cash Flow: -324230000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1157601/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -324230000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000162828026009514/mdgl-20251231.htm#1434014 Filing: 000162828026009514 The citation records this snapshot. The page link may show a newer release later.	USD 1.48 million Exact value Exact value: 1479000 USD 2023-01-01 – 2023-12-31: 1479000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Madrigal Pharmaceuticals, Inc. · 2023-12-31 Madrigal Pharmaceuticals, Inc. (edgar:1157601) Capital Expenditure: 1479000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1157601/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1479000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000162828026009514/mdgl-20251231.htm#1442812 Filing: 000162828026009514 The citation records this snapshot. The page link may show a newer release later.	−USD 325.71 million Calculation and evidence -324230000 − 1479000 USD Exact free cash flow: -325709000 USD 2023-01-01 – 2023-12-31: -324230000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 1479000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Madrigal Pharmaceuticals, Inc. · 2023-12-31 Madrigal Pharmaceuticals, Inc. (edgar:1157601) Free cash flow: -325709000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1157601?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -324230000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000162828026009514/mdgl-20251231.htm#1434014 Filing: 000162828026009514 Input fundies:CapitalExpenditure: 1479000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000162828026009514/mdgl-20251231.htm#1442812 Filing: 000162828026009514 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 465.89 million Exact value Exact value: -465892000 USD 2024-01-01 – 2024-12-31: -465892000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Madrigal Pharmaceuticals, Inc. · 2024-12-31 Madrigal Pharmaceuticals, Inc. (edgar:1157601) Net Income: -465892000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1157601/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -465892000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000162828026009514/mdgl-20251231.htm#1374983 Filing: 000162828026009514 The citation records this snapshot. The page link may show a newer release later.	−USD 455.57 million Exact value Exact value: -455572000 USD 2024-01-01 – 2024-12-31: -455572000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Madrigal Pharmaceuticals, Inc. · 2024-12-31 Madrigal Pharmaceuticals, Inc. (edgar:1157601) Operating Cash Flow: -455572000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1157601/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -455572000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000162828026009514/mdgl-20251231.htm#1433360 Filing: 000162828026009514 The citation records this snapshot. The page link may show a newer release later.	USD 1.46 million Exact value Exact value: 1462000 USD 2024-01-01 – 2024-12-31: 1462000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Madrigal Pharmaceuticals, Inc. · 2024-12-31 Madrigal Pharmaceuticals, Inc. (edgar:1157601) Capital Expenditure: 1462000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1157601/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1462000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000162828026009514/mdgl-20251231.htm#1442221 Filing: 000162828026009514 The citation records this snapshot. The page link may show a newer release later.	−USD 457.03 million Calculation and evidence -455572000 − 1462000 USD Exact free cash flow: -457034000 USD 2024-01-01 – 2024-12-31: -455572000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 1462000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Madrigal Pharmaceuticals, Inc. · 2024-12-31 Madrigal Pharmaceuticals, Inc. (edgar:1157601) Free cash flow: -457034000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1157601?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -455572000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000162828026009514/mdgl-20251231.htm#1433360 Filing: 000162828026009514 Input fundies:CapitalExpenditure: 1462000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000162828026009514/mdgl-20251231.htm#1442221 Filing: 000162828026009514 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 288.3 million Exact value Exact value: -288300000 USD 2025-01-01 – 2025-12-31: -288300000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Madrigal Pharmaceuticals, Inc. · 2025-12-31 Madrigal Pharmaceuticals, Inc. (edgar:1157601) Net Income: -288300000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1157601/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -288300000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000162828026009514/mdgl-20251231.htm#1534796 Filing: 000162828026009514 The citation records this snapshot. The page link may show a newer release later.	−USD 189.55 million Exact value Exact value: -189553000 USD 2025-01-01 – 2025-12-31: -189553000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Madrigal Pharmaceuticals, Inc. · 2025-12-31 Madrigal Pharmaceuticals, Inc. (edgar:1157601) Operating Cash Flow: -189553000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1157601/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -189553000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000162828026009514/mdgl-20251231.htm#1432706 Filing: 000162828026009514 The citation records this snapshot. The page link may show a newer release later.	USD 467,000 Exact value Exact value: 467000 USD 2025-01-01 – 2025-12-31: 467000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Madrigal Pharmaceuticals, Inc. · 2025-12-31 Madrigal Pharmaceuticals, Inc. (edgar:1157601) Capital Expenditure: 467000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1157601/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 467000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000162828026009514/mdgl-20251231.htm#1441661 Filing: 000162828026009514 The citation records this snapshot. The page link may show a newer release later.	−USD 190.02 million Calculation and evidence -189553000 − 467000 USD Exact free cash flow: -190020000 USD 2025-01-01 – 2025-12-31: -189553000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 467000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Madrigal Pharmaceuticals, Inc. · 2025-12-31 Madrigal Pharmaceuticals, Inc. (edgar:1157601) Free cash flow: -190020000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1157601?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -189553000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000162828026009514/mdgl-20251231.htm#1432706 Filing: 000162828026009514 Input fundies:CapitalExpenditure: 467000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1157601/000162828026009514/mdgl-20251231.htm#1441661 Filing: 000162828026009514 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

113 filings · 3,441 latest values · 3,441 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001157601, 1157601, MDGL, edgar:1157601

Also known as MADRIGAL PHARMACEUTICALS, INC., MADRIGAL PHARMACEUTICALS, INC., Madrigal Pharmaceuticals, Inc., SYNTA PHARMACEUTICALS CORP

Madrigal Pharmaceuticals, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation